Researchers at Mayo Clinic presented data at DDW 2026 demonstrating that the TissueCypher molecular test enhances risk stratification for Barrett's esophagus patients. The test better predicts progression to serious conditions like high-grade dysplasia or esophageal cancer compared to traditional methods, leading to changes in surveillance intervals for over half of patients. This allows for more personalized, risk-aligned management, potentially improving outcomes by escalating care for higher-risk patients and reducing unnecessary procedures for lower-risk individuals. The findings support integrating TissueCypher into clinical practice to guide more effective patient monitoring and treatment decisions.
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
US stock futures showed mixed results with the S&P 500 slightly down while the Dow Jones and Nasdaq 100 edged higher following a recent rally. The market reacted to a preliminary US-Iran agreement aimed at extending a ceasefire and reopening the Stra...
MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce co...
Space Exploration Technologies Corp. (SpaceX) saw its shares surge over 11% in premarket trading, pushing its market capitalization close to $3 trillion, surpassing Amazon to become the fifth-largest company globally. This rapid valuation increase ha...
